Isosorbide mononitrate
Isosorbide mononitrate.svg
Names
Trade namesMonoket, Imdur, others
  • 8-nitrooxy-2,6-dioxabicyclo[3.3.0]octan-4-ol
Clinical data
Pregnancy
category
  • AU: B2[1]
  • US: C (Risk not ruled out)or B (manufacturer dependent)[1]
Routes of
use		By mouth
Defined daily dose40 mg[2]
External links
AHFS/Drugs.comMonograph
MedlinePlusa682348
Legal
License data
Legal status
Pharmacokinetics
Bioavailability>95%
Protein binding<5%
MetabolismHepatic
Elimination half-life5 hours
ExcretionKidney (93%)
Chemical and physical data
FormulaC6H9NO6
Molar mass191.139 g·mol−1
3D model (JSmol)
  • [O-][N+](=O)O[C@H]1[C@H]2OC[C@H](O)[C@H]2OC1
  • InChI=1S/C6H9NO6/c8-3-1-11-6-4(13-7(9)10)2-12-5(3)6/h3-6,8H,1-2H2/t3-,4+,5+,6+/m0/s1 checkY
  • Key:YWXYYJSYQOXTPL-SLPGGIOYSA-N checkY

Isosorbide mononitrate, sold under many brand names, is a medication used for heart-related chest pain (angina), heart failure, and esophageal spasms.[3] It can be used both to treat and to prevent heart-related chest pain; however, it is generally less preferred than beta blockers or calcium channel blockers.[3] It is taken by mouth.[3]

Common side effects include headache, low blood pressure with standing, blurry vision, and skin flushing.[3] Serious side effects may include low blood pressure especially if also exposed to PDE5 inhibitors such as sildenafil.[3] Use is not recommended in pregnancy.[4] It is believed to work by relaxing smooth muscle within blood vessels.[3]

It was patented in 1971 and approved for medical use in 1981.[5] It is available as a generic medication.[4] A month's supply in the United Kingdom costs the NHS about one pound sterling per month as of 2019.[4] In the United States the wholesale cost of this amount is about US$4.30.[6] In 2017, it was the 111th most commonly prescribed medication in the United States, with more than six million prescriptions.[7][8]

Medical uses[edit | edit source]

Isosorbide mononitrate is a nitrate-class drug used for the prevention of angina pectoris.[9]

Dosage[edit | edit source]

The defined daily dose is 40 mg by mouth.[2]

Side effects[edit | edit source]

The following Side effects have been reported:

Very common: Headache predominates (up to 30%) necessitating withdrawal of 2 to 3% of patients, but the incidence reduces rapidly as treatment continues.[9]

Common: Tiredness, sleep disturbances (6%) and gastrointestinal disturbances (6%) have been reported during clinical trials with isosorbide mononitrate modified-release tablets, but at a frequency no greater than for placebo. Hypotension (4 to 5%), poor appetite (2.5%), nausea (1%)[9]

Adverse effects associated with the clinical use of the drug are as expected with all nitrate preparations. They occur mainly in the early stages of treatment.[9]

Hypotension (4%) with symptoms such as dizziness and nausea (1%) have been reported. In general, these symptoms disappear during long-term treatment.[9]

Other reactions that have been reported with isosorbide mononitrate-modified release tablets include tachycardia, vomiting, diarrhoea, vertigo, and heartburn.[9]

Interactions[edit | edit source]

Brand names[edit | edit source]

It is sold in the US by Lannett Company, under the trade name Monoket,[9][10] and was also sold in the US under the name Imdur,[11] and marketed in the UK under the trade names: Isotard, Monosorb, Chemydur. In India, this drug is available under the brand names of Ismo, Imdur, Isonorm, Monotrate, Solotrate, and Monit. In Russia it is occasionally used under the brand names Monocinque and Pektrol. In Australia, this drug is available under the brand name Duride.[citation needed]

Society and culture[edit | edit source]

Cost[edit | edit source]

A month's supply in the United Kingdom costs the NHS about one pound sterling per month as of 2019.[4] In the United States the wholesale cost of this amount is about US$4.30.[6]In 2017, it was the 111th most commonly prescribed medication in the United States, with more than six million prescriptions.[7][8]

References[edit | edit source]

  1. ↑ 1.0 1.1 "Isosorbide mononitrate Use During Pregnancy". Drugs.com. 28 February 2020. Archived from the original on 25 January 2021. Retrieved 14 April 2020.
  2. ↑ 2.0 2.1 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 11 July 2020. Retrieved 6 September 2020.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 "Isosorbide Dinitrate/Mononitrate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 3 March 2019.
  4. ↑ 4.0 4.1 4.2 4.3 British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 219–220. ISBN 9780857113382.
  5. ↑ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 454. ISBN 9783527607495. Archived from the original on 2016-12-20. Retrieved 2019-02-28.
  6. ↑ 6.0 6.1 "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 2019-03-06. Retrieved 3 March 2019.
  7. ↑ 7.0 7.1 "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
  8. ↑ 8.0 8.1 "Isosorbide Mononitrate - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.
  9. ↑ 9.0 9.1 9.2 9.3 9.4 9.5 9.6 9.7 9.8 "Monoket- isosorbide mononitrate tablet". DailyMed. 3 February 2015. Archived from the original on 28 August 2021. Retrieved 14 April 2020.
  10. ↑ "Monoket: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 29 June 2017. Retrieved 14 April 2020.
  11. ↑ "Imdur: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 29 August 2021. Retrieved 14 April 2020.

External links[edit | edit source]

Identifiers: